糖尿病性胃不全麻痺(Diabetic Gastroparesis):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Diabetic Gastroparesis - Pipeline Review, H1 2015
◆商品コード:GMDHC6307IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年2月18日
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における糖尿病性胃不全麻痺(Diabetic Gastroparesis)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・糖尿病性胃不全麻痺(Diabetic Gastroparesis)の概要
・糖尿病性胃不全麻痺(Diabetic Gastroparesis)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・糖尿病性胃不全麻痺(Diabetic Gastroparesis)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・糖尿病性胃不全麻痺(Diabetic Gastroparesis)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・糖尿病性胃不全麻痺(Diabetic Gastroparesis)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Diabetic Gastroparesis – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Diabetic Gastroparesis – Pipeline Review, H1 2015’, provides an overview of the Diabetic Gastroparesis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Gastroparesis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Diabetic Gastroparesis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Gastroparesis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diabetic Gastroparesis Overview 7
Therapeutics Development 8
Pipeline Products for Diabetic Gastroparesis – Overview 8
Pipeline Products for Diabetic Gastroparesis – Comparative Analysis 9
Diabetic Gastroparesis – Therapeutics under Development by Companies 10
Diabetic Gastroparesis – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Diabetic Gastroparesis – Products under Development by Companies 14
Diabetic Gastroparesis – Companies Involved in Therapeutics Development 15
Cempra, Inc. 15
Evoke Pharma, Inc. 16
GlaxoSmithKline plc 17
Ironwood Pharmaceuticals, Inc. 18
Rhythm Pharmaceuticals 19
Shire Plc 20
Targacept, Inc. 21
Diabetic Gastroparesis – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
camicinal – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ETX-101 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ETX-301 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
IW-9179 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
metoclopramide hydrochloride – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
prucalopride succinate – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
relamorelin – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
TC-6499 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
velusetrag – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Diabetic Gastroparesis – Recent Pipeline Updates 46
Diabetic Gastroparesis – Dormant Projects 53
Diabetic Gastroparesis – Discontinued Products 54
Diabetic Gastroparesis – Product Development Milestones 55
Featured News & Press Releases 55
Feb 02, 2015: Evoke Pharma Outlines Progress on Clinical Program 55
Dec 09, 2014: Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis 55
Dec 02, 2014: Evoke Pharma’s EVK-001 Showed No QT Prolongation in Thorough ECG (TQT) Study 56
Sep 09, 2014: Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001 57
Aug 12, 2014: Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001 57
Jun 25, 2014: Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis 57
May 28, 2014: Evoke Pharma Secures $4.5 Million Loan Facility With Square 1 Bank 58
May 06, 2014: Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis 59
Jan 22, 2014: Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics 60
Oct 15, 2013: Targacept Scientists to Present Data On TC-6499 at Society for Neuroscience Satellite Meeting 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

[List of Tables]
Number of Products under Development for Diabetic Gastroparesis, H1 2015 8
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Diabetic Gastroparesis - Pipeline by Cempra, Inc., H1 2015 15
Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H1 2015 16
Diabetic Gastroparesis - Pipeline by GlaxoSmithKline plc, H1 2015 17
Diabetic Gastroparesis - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 18
Diabetic Gastroparesis - Pipeline by Rhythm Pharmaceuticals, H1 2015 19
Diabetic Gastroparesis - Pipeline by Shire Plc, H1 2015 20
Diabetic Gastroparesis - Pipeline by Targacept, Inc., H1 2015 21
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Diabetic Gastroparesis Therapeutics - Recent Pipeline Updates, H1 2015 46
Diabetic Gastroparesis - Dormant Projects, H1 2015 53
Diabetic Gastroparesis - Discontinued Products, H1 2015 54

[List of Figures]
Number of Products under Development for Diabetic Gastroparesis, H1 2015 8
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Assessment by Monotherapy Products, H1 2015 22
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 24
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Top 10 Routes of Administration, H1 2015 27
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28
Number of Products by Top 10 Molecule Types, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

【掲載企業】

Cempra, Inc.
Evoke Pharma, Inc.
GlaxoSmithKline plc
Ironwood Pharmaceuticals, Inc.
Rhythm Pharmaceuticals
Shire Plc
Targacept, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[糖尿病性胃不全麻痺(Diabetic Gastroparesis):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆